Novonesis (Novozymes) stock (DK0060336014): integration progress and earnings keep biotech group in focus

Novonesis, formed from the merger of Novozymes and Chr. Hansen, stays in the spotlight after recent first?quarter results and integration updates. US investors watch the enzyme and biosolutions specialist as it refines guidance and details cost synergies.

Novonesis, the biosolutions company created from the combination of Novozymes and Chr. Hansen, has remained in focus after publishing its first?quarter 2025 results and updating investors on integration progress and synergy targets, according to a company announcement dated April 24, 2025 on its investor website Novonesis investor communication as of 04/24/2025. The group reported organic sales growth in line with its full?year outlook and confirmed expected cost synergies, while reiterating guidance for 2025.

The company said that organic revenue growth for the first quarter of 2025 was mid?single?digit, with particular support from household care enzymes and food & beverage applications, and it confirmed that full?year 2025 organic growth is expected in the mid? to high?single?digit range, according to the same announcement Novonesis investor communication as of 04/24/2025. Management also highlighted that the integration of the legacy Novozymes and Chr. Hansen portfolios is on track, including portfolio pruning and organizational restructuring designed to capture synergies.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novonesis
• Sector/industry: Industrial biotechnology, enzymes and microbial solutions
• Headquarters/country: Denmark
• Core markets: Global, with meaningful exposure to Europe, North America and Asia
• Key revenue drivers: Enzymes and microbial solutions for household care, food & beverage, agriculture, and bioenergy
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NVNS)
• Trading currency: Danish krone (DKK)

Novonesis: core business model

Novonesis operates as a biosolutions specialist, focusing on enzymes, cultures and microbial technologies that help customers improve efficiency and sustainability in their production processes. The company emerged after the combination of Danish groups Novozymes and Chr. Hansen, a transaction that was completed in early 2024 following regulatory approvals, according to earlier company statements published in 2023 and 2024 on the respective investor pages Novonesis investor communication as of 01/29/2024.

The core idea behind the merger was to bring together complementary portfolios in food cultures, enzymes and probiotics to create a larger platform with broader scale and research capabilities. Novozymes historically specialized in industrial enzymes for detergents, textiles, bioenergy and food processing, while Chr. Hansen was known for microbial and fermentation technologies for dairy, probiotics and agriculture. Management has emphasized that the combined group should be able to offer more integrated solutions across end markets, according to merger?related documentation published in 2023 and 2024 Chr. Hansen investor communication as of 12/12/2023.

Revenue is generated primarily through long?term relationships with industrial customers, consumer?goods companies and food manufacturers. These clients typically use Novonesis technologies as functional ingredients or processing aids, benefiting from improved product performance, reduced resource consumption or enhanced shelf life. Because the solutions are deeply embedded in manufacturing processes and formulations, switching suppliers can be complex, which tends to support relatively resilient demand across cycles, as management underlined during capital markets presentations in 2024.

From a financial perspective, Novonesis aims for organic growth underpinned by continued innovation and penetration of enzyme and microbial solutions in applications that still rely partly on traditional chemistry. The company invests a significant share of revenue in research and development to maintain a pipeline of new products, including strains and enzyme formulations tailored to specific customer needs. Management has also stressed the importance of cost discipline and synergy capture after the merger, targeting a stronger margin profile over time, according to the first?quarter 2025 earnings communication published on April 24, 2025 Novonesis investor communication as of 04/24/2025.

Main revenue and product drivers for Novonesis

A major revenue driver for Novonesis is the household care segment, where the company supplies enzyme solutions for laundry and dishwashing detergents. These products help improve stain removal at lower temperatures and enable formulators to reduce the use of certain chemical ingredients. In its first?quarter 2025 report, Novonesis highlighted solid demand in this area, especially in emerging markets, which contributed to mid?single?digit organic growth for the period, according to the company’s April 24, 2025 announcement Novonesis investor communication as of 04/24/2025.

Food and beverage applications also represent an important part of the business. The company offers enzymes and cultures that are used in baking, dairy, brewing and other categories to improve texture, flavor, shelf life and production efficiency. Demand in these areas is influenced by consumer trends such as higher protein intake, lower sugar content and more natural ingredients. Novonesis noted that its food & beverage sales showed stable development in early 2025, supported by innovation and cross?selling opportunities between the legacy Novozymes and Chr. Hansen portfolios, according to the same quarterly communication.

Another contributor is agriculture and animal health, where microbial and probiotic solutions can support crop yields or improve feed efficiency and gut health in livestock. These products are typically marketed as alternatives or complements to more traditional crop protection and feed?additive approaches. The company has previously indicated that regulatory trends favoring reduced antibiotic usage and more sustainable farming practices could support long?term demand in this segment, as described in presentations around the merger published in 2023 and 2024 Novonesis investor information as of 03/21/2024.

Bioenergy and technical solutions round out the portfolio. In bioenergy, Novonesis supplies enzymes that increase yields in ethanol production, particularly in North America where corn?based biofuels remain a significant outlet. For technical industries, the company offers enzymes that help reduce resource consumption, for instance in textile processing or pulp and paper. Management has described demand in these cyclical segments as more volatile, but still strategically important, both for revenue diversification and for demonstrating the potential of biosolutions to reduce environmental footprints across industries.

Why Novonesis matters for US investors

Although Novonesis is headquartered and listed in Denmark, its products are widely used by multinational consumer?goods companies and industrial players with substantial operations in the United States. Household care enzymes and bioenergy solutions in particular are closely linked to US demand, including laundry detergents sold in North America and enzymes used in US ethanol production, as described in company presentations published in 2024 and 2025 Novonesis results and events as of 11/06/2024.

For US investors who follow global industrial biotechnology and sustainable materials, Novonesis can serve as an indicator of broader trends in enzyme adoption and bio?based solutions. Developments in its quarterly results, guidance and capital allocation may provide additional context when assessing peers that are listed in the US but exposed to similar end markets, such as detergents, food ingredients or biofuels. In addition, currency movements between the US dollar and Danish krone, as well as regulatory changes affecting biofuels or agricultural inputs, can influence the company’s reported performance and may be of interest to US?based shareholders.

Conclusion

Novonesis is progressing with the integration of Novozymes and Chr. Hansen while reporting organic growth in line with its full?year targets, based on its first?quarter 2025 update published on April 24, 2025. The company remains focused on capturing cost synergies, refining its combined product portfolio and investing in research and development to support future growth. For US investors following global biosolutions and industrial biotechnology, the stock illustrates how demand for enzymes and microbial technologies is evolving across household care, food, agriculture and bioenergy. At the same time, the group faces the usual execution risks tied to large integrations, macroeconomic uncertainty and regulatory developments in its key markets, which investors will continue to watch closely through upcoming results and capital markets communications.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.